|
1
|
Angulo P, Kaushik G, Subramaniam D,
Dandawate P, Neville K, Chastain K and Anant S: Natural compounds
targeting major cell signaling pathways: A novel paradigm for
osteosarcoma therapy. J Hematol Oncol. 10:102017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ferrari S and Serra M: An update on
chemotherapy for osteosarcoma. Expert Opin Pharmacother.
16:2727–2736. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Isakoff MS, Bielack SS, Meltzer P and
Gorlick R: Osteosarcoma: Current treatment and a collaborative
pathway to success. J Clin Oncol. 33:3029–3035. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Chen Y, Xu SF, Xu M and Yu XC: Intentional
marginal resection of periosteal osteosarcoma in combination with
neoadjuvant chemotherapy: A report of two cases and a review of the
literature. Oncol Lett. 13:1343–1347. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hirotsu M, Setoguchi T, Sasaki H,
Matsunoshita Y, Gao H, Nagao H, Kunigou O and Komiya S: Smoothened
as a new therapeutic target for human osteosarcoma. Mol Cancer.
9:52010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Margue C, Reinsbach S, Philippidou D,
Beaume N, Walters C, Schneider JG, Nashan D, Behrmann I and Kreis
S: Comparison of a healthy miRNome with melanoma patient miRNomes:
Are microRNAs suitable serum biomarkers for cancer? Oncotarget.
6:12110–12127. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Guo K, Liang Z, Li F and Wang H:
Comparison of miRNA and gene expression profiles between metastatic
and primary prostate cancer. Oncol Lett. 14:6085–6090.
2017.PubMed/NCBI
|
|
8
|
Sun B, Liu X, Gao Y, Li L and Dong Z:
Downregulation of miR-124 predicts poor prognosis in pancreatic
ductal adenocarcinoma patients. Br J Biomed Sci. 73:152–307. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ohzawa H, Miki A, Teratani T, Shiba S,
Sakuma Y, Nishimura W, Noda Y, Fukushima N, Fujii H, Hozumi Y, et
al: Usefulness of miRNA profiles for predicting pathological
responses to neoadjuvant chemotherapy in patients with human
epidermal growth factor receptor 2-positive breast cancer. Oncol
Lett. 13:1731–1740. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Gee HE, Ivan C, Calin GA and Ivan M:
HypoxamiRs and cancer: From biology to targeted therapy. Antioxid
Redox Signal. 21:1220–1238. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Manikandan J, Aarthi JJ, Kumar SD and
Pushparaj PN: Oncomirs: The potential role of non-coding microRNAs
in understanding cancer. Bioinformation. 2:330–334. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Paudel D, Zhou W, Ouyang Y, Dong S, Huang
Q, Giri R, Wang J and Tong X: MicroRNA-130b functions as a tumor
suppressor by regulating RUNX3 in epithelial ovarian cancer. Gene.
586:48–55. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhuang LK, Yang YT, Ma X, Han B, Wang ZS,
Zhao QY, Wu LQ and Qu ZQ: MicroRNA-92b promotes hepatocellular
carcinoma progression by targeting Smad7 and is mediated by long
non-coding RNA XIST. Cell Death Dis. 7:e22032016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wu D, Huang P, Wang L, Zhou Y, Pan H and
Qu P: MicroRNA-143 inhibits cell migration and invasion by
targeting matrix metalloproteinase 13 in prostate cancer. Mol Med
Rep. 8:626–630. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhang S, Lai N, Liao K, Sun J and Lin Y:
MicroRNA-210 regulates cell proliferation and apoptosis by
targeting regulator of differentiation 1 in glioblastoma cells.
Folia Neuropathol. 53:236–244. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Liu D, Xia H, Wang F, Chen C and Long J:
MicroRNA-210 interacts with FBXO31 to regulate cancer proliferation
cell cycle and migration in human breast cancer. Onco Targets Ther.
9:5245–5255. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Amponsah PS, Fan P, Bauer N, Zhao Z,
Gladkich J, Fellenberg J and Herr I: microRNA-210 overexpression
inhibits tumor growth and potentially reverses gemcitabine
resistance in pancreatic cancer. Cancer Lett. 388:107–117. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Trueb B: Biology of FGFRL1, the fifth
fibroblast growth factor receptor. Cell Mol Life Sci. 68:951–964.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhuang L, Karotki AV, Bruecker P and Trueb
B: Comparison of the receptor FGFRL1 from sea urchins and humans
illustrates evolution of a zinc binding motif in the intracellular
domain. BMC Biochem. 10:332009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kähkönen TE, Ivaska KK, Jian M, Büki KG,
Väänänen HK and Härkönen PL: Role of fibroblast growth factor
receptors (FGFR) and FGFR like-1 (FGFRL1) in mesenchymal stromal
cell differentiation to osteoblasts and adipocytes. Mol Cell
Endocrinol. 461:194–204. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Sun Z, Liu Q, Hong H, Zhang H and Zhang T:
miR-19 promotes osteosarcoma progression by targeting SOCS6.
Biochem Biophys Res Commun. 495:1363–1369. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Urciuoli E, Coletta I, Rizzuto E, De Vito
R, Petrini S, D'Oria V, Pezzullo M, Milano GM, Cozza R, Locatelli F
and Peruzzi B: Src nuclear localization and its prognostic
relevance in human osteosarcoma. J Cell Physiol. 233:1658–1670.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wang D, Song Z and Wang Z: Common
mechanism of pathogenesis in various types of metastatic
osteosarcoma. Oncol Lett. 14:6307–6313. 2017.PubMed/NCBI
|
|
25
|
Luo T, Yi X and Si W: Identification of
miRNA and genes involving in osteosarcoma by comprehensive analysis
of microRNA and copy number variation data. Oncol Lett.
14:5427–5433. 2017.PubMed/NCBI
|
|
26
|
Diao H, Liu B, Shi Y, Song C, Guo Z, Liu
N, Song X, Lu Y, Lin X and Li Z: MicroRNA-210 alleviates oxidative
stress-associated cardiomyocyte apoptosis by regulating BNIP3.
Biosci Biotechnol Biochem. 81:1712–1720. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wang Z, Deng M, Liu Z and Wu S:
Hypoxia-induced miR-210 promoter demethylation enhances
proliferation, autophagy and angiogenesis of schwannoma cells.
Oncol Rep. 37:3010–3018. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Li Y, Yang C, Zhang L and Yang P:
MicroRNA-210 induces endothelial cell apoptosis by directly
targeting PDK1 in the setting of atherosclerosis. Cell Mol Biol
Lett. 22:32017. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yang X, Shi L, Yi C, Yang Y, Chang L and
Song D: MiR-210-3p inhibits the tumor growth and metastasis of
bladder cancer via targeting fibroblast growth factor receptor-like
1. Am J Cancer Res. 7:1738–1753. 2017.PubMed/NCBI
|
|
30
|
Ruan K, Song G and Ouyang G: Role of
hypoxia in the hallmarks of human cancer. J Cell Biochem.
107:1053–1062. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Arvelo F and Cotte C: Hypoxia in cancer
malignity. Review. Invest Clin. 50:529–546. 2009.(In Spanish).
PubMed/NCBI
|
|
32
|
Qin Q, Furong W and Baosheng L: Multiple
functions of hypoxia-regulated miR-210 in cancer. J Exp Clin Cancer
Res. 33:502014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Beenken A and Mohammadi M: The FGF family:
Biology, pathophysiology and therapy. Nat Rev Drug Discov.
8:235–253. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zhou WY, Zheng H, Du XL and Yang JL:
Characterization of FGFR signaling pathway as therapeutic targets
for sarcoma patients. Cancer Biol Med. 13:260–278. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zhuang L, Steinberg F and Trueb B:
Receptor FGFRL1 acts as a tumor suppressor in nude mice when
overexpressed in HEK 293 Tet-On cells. Oncol Lett. 12:4524–4530.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Yang X, Steinberg F, Zhuang L, Bessey R
and Trueb B: Receptor FGFRL1 does not promote cell proliferation
but induces cell adhesion. Int J Mol Med. 38:30–38. 2016.
View Article : Google Scholar : PubMed/NCBI
|
